Increased expression of TGFb isoforms in human endometrial cancer correlates with decreased survival and poor prognosis. Progesterone has been shown to exert a chemoprotective effect against endometrial cancer, and previous animal models have suggested that these effects are accompanied by changes in TGFb. The goal of this study was to characterize the effect of progesterone on TGFb signaling pathway components and on TGFb-induced protumorigenic activities in endometrial cancer cell lines. Progesterone significantly decreased expression of three TGFb isoforms at 72 hours after treatment except for TGFb2 in HEC-1B and TGFb3 in Ishikawa cells. Progesterone treatment for 120 hours attenuated expression of the three isoforms in all cell lines. Progesterone exposure for 72 hours reduced expression of TGFb receptors in HEC-1B cells and all but TGFbR1 in Ishikawa cells. Progesterone reduced TGFbR3 expression in RL-95 cells at 72 hours, but TGFbR1 and bR2 expression levels were not affected by progesterone at any time point. SMAD2/3 and pSMAD2/3 were substantially reduced at 72 hours in all cell lines. SMAD4 expression was reduced in RL-95 cells at 24 hours and in HEC-1B and Ishikawa cells at 72 hours following progesterone treatment. Furthermore, progesterone effectively inhibited basal and TGFb1-induced cancer cell viability and invasion, which was accompanied by increased E-cadherin and decreased vimentin expression. An inhibitor of TGFbRI blocked TGFb1-induced effects on cell viability and invasion and attenuated antitumor effects of progesterone. These results suggest that downregulation of TGFb signaling is a key mechanism underlying progesterone inhibition of endometrial cancer growth. Cancer Prev Res; 7(10); 1045-55. Ó2014 AACR.
Introduction
The TGFb family members are secreted cytokines that regulate a broad array of cellular responses, including proliferation, differentiation, migration, and apoptosis (1, 2) . The role of TGFb in tumor biology is complex. It has tumor-suppressing activity in the early stages of carcinogenesis, whereas in the later stages of carcinogenesis, it functions as a tumor promoter (2, 3) . The growth-inhibitory function of TGFb is selectively lost in advanced cancers due to mutational inactivation or dysregulated expression of various components of the TGFb signaling pathway resulting in growth, invasion, and metastasis of cancer cells (4) .
Human endometrial tumors contain the three TGFb isoforms in both the epithelial and stromal counterparts of the tumors, and these proteins are responsible for autocrine as well as paracrine signaling in the microenvironment of these tumors. The different TGFb isoforms can sometimes differentially activate signaling pathways in cancer cells, leading to isoform-specific effects on cellular phenotype (5, 6) .
Overexpression of TGFb1 has been reported in many (pancreas, breast, prostate, ovary, and endometrium) tumors and is associated with metastatic phenotypes and poor patient outcome (7, 8) . TGFb1 signals are largely known as tumor promoters of cellular responses such as proliferation, survival, migration, and invasion (4) . Compared with TGFb2 and TGFb3, high levels of TGFb1 are reported in endometrial cancer cell lines and these findings are corroborated with abundant TGFb1 immunoreactivity in human endometrial tumors in vivo (8) .
TGFb2 is expressed in a variety of cancer cell lines, including glioma, prostate, breast, lung and kidney, and endometrium (5) . In endometrial cancer of the three isoforms, TGFb2 is the least expressed. Increase of TGFb2 protein levels was observed in advanced-stage endometrial tumors (9) . TGFb2 promotes the survival of tumor cells by activating NF-kB. Suppression of TGFb2 expression by siRNA attenuates cancer cells growth, indicating that the TGFb2-NF-kB pathway is important for viability of tumor cells (5) .
High levels of TGFb3 are detected in the glands in endometrial carcinoma compared with TGFb3 detected by immunostaining in the glandular epithelial cells of the normal proliferative and secretory endometrium (6) . TGFb3 is shown to increase invasiveness of endometrial cancer (KLE and HEC-1A) cells through two signaling pathways: PI3K-dependent upregulation of X-linked inhibitor of apoptosis protein and through protein kinase C-dependent induction of matrix metalloproteinase-9 (MMP-9) expression (6) . Upon progression toward a more invasive phenotype (from stage I to stage III endometrial adenocarcinoma), TGFb3 immunoreactivity gradually extends from the epithelial compartment (in normal tissues) to the stroma (in adenocarcinoma), consistent with a role for TGFb3 in endometrial cancer cell invasiveness (6, 8) .
TGFb ligands bind to TGFb receptor type 2 (TGFbR2), a constitutively active transmembrane serine/threonine kinase, and forms an oligomeric complex with TGFb receptor type 1 (TGFbR1). TGFbR1 is phosphorylated by the TGFbR2. The activated TGFbR1 initiates intracellular signaling through phosphorylation of specific receptor-regulated (R)-SMAD proteins (SMAD2 and SMAD3). Activated (R)-SMADs form a complex with SMAD4, and the complex translocates to the nucleus, where it binds to DNA in a sequence-specific manner, and regulates gene transcription (3, 4) .
Immunohistochemical analysis has shown higher expression of TGFbR1, TGFbR2, and TGFbR3 in endometrial tumors compared with normal tissues (10, 11) . Deregulation of TGFbR3 expression not only results in loss of antiproliferative activity of TGFb signaling at early stages of endometrial cancer development but also leads to acquisition of cell motility. High TGFbR3 expression plays a role in mediating cell proliferation and migration in endometrial tumors (9) . TGFbR3 binds all three TGFb isoforms. The function of TGFbR3 is to present ligands to TGFbR2 and TGFbR1, which, upon ligand binding, transphosphorylate to activate the type I TGFbR1 (12, 13) .
An important step in the metastatic process is epithelial to mesenchymal transition (EMT), in which adherent and nonmotile epithelial cells acquire motility and invasiveness (14) . Increased expression of TGFb induces EMT by enhancing the expression of zinc-finger transcriptional factors Snail and Slug and downregulating expression of epithelial marker E-cadherin, which is critical in mediating epithelial cell integrity and cell-cell adhesion (15) . Subsequently, mesenchymal markers N-cadherin, vimentin, and MMP proteins are elevated and thus cell motility and invasive phenotypes (14, 16) . Cancer cells overexpressing active TGFb have increased metastatic ability (17, 18) , and targeting of TGFb signaling prevents metastasis in several neoplastic tumors, including breast, prostate, and colorectal cancers (19) (20) (21) .
Progestins are highly effective endometrial cancer-preventive agents. Extensive epidemiologic investigations demonstrate that long-term progestins use is associated with significant endometrial cancer risk reduction (22) (23) . Progesterone has also been used as a primary treatment for endometrial carcinoma in premenopausal women, and response rates in these women can be as high as 60%, indicating that progesterone is a potent inhibitor of endometrial carcinogenesis (24, 25) . Recent studies in primates have demonstrated a potential mechanism underlying the chemopreventive effect of progestins [levonorgestrel and medroxyprogesterone acetate (MPA)] against ovarian and endometrial cancer. Progestin exposure was associated with increased apoptosis and a concomitant marked decrease in the expression of TGFb1 in the ovarian and endometrial glandular epithelium, and a concomitant increase in the expression of TGFb2 and 3 in the ovarian epithelium and endometrial stroma, respectively (26, 27) . This suggests that the antitumorigenic effects of levonorgestrel and MPA may be at least, in part, mediated by altering the expression of TGFb signaling components.
Despite the importance of TGFb in regulating several endometrial cellular activities (4, 28) , the effect of progesterone on the expression and regulation of TGFb signaling components in human endometrial cancer has not been well characterized. In the present study, we examined the effect of progesterone on the TGFb/SMAD signaling pathway in endometrial cancer cells and showed that progesterone inhibits TGFb-induced R-SMAD expression, nuclear translocation, and subsequently attenuates tumor cell growth and invasiveness by decreasing vimentin and increasing E-cadherin.
Materials and Methods

Cell culture and treatment
Human endometrial cancer cell lines HEC-1B and RL-95 were obtained from the ATCC and the Ishikawa cell line was obtained from Sigma. The cell lines were authenticated by DNA short-tandem repeat analysis by the ATCC and Sigma. All three cell lines were initially expanded and cryopreserved within 1 month of receipt. Cells were typically used for 3 months, at which time a fresh vial of cryopreserved cells was used. The cells were routinely tested for mycoplasma. Ishikawa cells were grown in DMEM:F12 supplemented with insulin (Invitrogen), HEC-1B cells were cultured in Eagle minimum essential medium (Invitrogen), and RL-95 cells were grown in DMEM:F12 medium supplemented with insulin (0.005 mg/mL). All three media were supplemented with 10% (v/v) FBS (Invitrogen), 100 U/mL penicillin, and 100 U/mL streptomycin. The cells were cultured at 37 C in a humidified atmosphere containing 5% CO 2 . Forty-eight hours later, the media were replaced with same media but containing charcoal-stripped FBS. The cells were treated with progesterone (20 mmol/L, 99.9% pure; Sigma) for 24, 72, and 120 hours and collected for protein extraction. The time of treatment and dose of progesterone was based on our previous studies showing inhibition of cell growth and apoptosis of cancer cells (29) . For a set of experiments, cells were treated with progesterone (20 mmol/L) or TGFb1 (10 ng/mL) in the presence or absence of TGFbR1 blocker (SD-208, 10mmol/L; Santa Cruz Biotechnology) for 72 hours and the effects on cell viability and invasion were assessed. Progesterone solution was in absolute ethanol, TGFb1 solution was in aqueous saline, and TGFbR1 blocker was in DMSO. The final concentrations of ethanol and DMSO in the media were 0.1%. Untreated control cultures were exposed to equal concentrations of ethanol, aqueous saline, or DMSO vehicle alone.
Measurement of TGFb1 concentration in the conditioned media
To study the effect of progesterone on the secretion of TGFb in culture, endometrial cells were treated for 72 hours with progesterone or TGFb1 in the absence or presence of progesterone receptor antagonist Mifepristone (0.1 mmol/L). After culture, cells were removed by centrifugation and the cell-free media were collected and stored at À80 C until use. After thawing at room temperature, the media were assayed for immunoreactive latent TGFb by enzyme-linked immunosorbent assay (BioLegend) according to the manufacturer's specifications with absorbance at 450 nm in a plate reader (ELX800). The immunoassay kit used in this experiment offered a dynamic range starting in the low ng/mL and covered three logarithms. Experiments were repeated at least three times with different media to minimize the intra-and interassay variation.
Cell viability assay
Cell viability of endometrial cancer cells treated with progesterone, TGFb1, or the combination in the presence or absence of TGFbR1 blocker was evaluated using the CellTiter 96 AQueous One Solution cell viability assay (Promega) according to the instructions of the manufacturer. CellTiter 96 AQueous One Solution reagent (20 mL) was added into each well of the 96-well assay plate containing the samples in 100 mL of culture medium. Absorbance was measured at 490 nm using an ELX800 microtiter Reader. Relative cell viability was expressed as percent change of treated cells over vehicle-treated cells.
Cell invasion assay
Endometrial cancer cells treated with progesterone, TGFb1, or the combination in the presence or absence of TGFbR1 blocker for 72 hours were detached by trypsin and resuspended in serum-free medium. Medium containing 10% FBS medium was applied to the lower chambers of BD BioCoat Matrigel Invasion Chambers (BD Biosciences) as chemoattractant, and then, cells were seeded on the upper chambers at a density of 2.5 Â 10 4 cells per well in 100 mL of serum-free medium without progesterone or TGFb1. The chambers were incubated for 16 to 18 hours at 37 C. At the end of incubation, noninvading cells were removed from the upper surface of the membrane by scrubbing. The cells on the lower surface of the membrane were fixed for 2 minutes in 100% methanol and stained with 1% toluidine blue in 1% sodium borate for 2 minutes. Excess stain was removed by rinsing the inserts with water. Each membrane was removed from the insert and placed on a microscope slide. The cover slip was placed on the slide and cells were counted in five random fields per slide. All slides were coded to avoid biased counting. The assay was run in triplicates.
Western blot analysis
Cell lysates were prepared in RIPA buffer [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 0.5% deoxycholate, 1.0% NP40, and 0.1% SDS] supplemented with a protease inhibitor mixture solution (Roche Molecular Biochemicals). After sonication, cell debris was pelleted by centrifugation, and protein concentration was determined with the BCA Protein Assay Reagent (Pierce). Equivalent amounts of proteins were resolved by 10% SDS-PAGE and transferred to PVDF membranes. The blots were then incubated with primary antibodies against TGFb1, TGFb2, TGFb3, TGFbR1, TGFbR2, TGFbR3, pSMAD2/3, SMAD2/ 3, SMAD4 (Santa Cruz Biotechnology), E-cadherin, vimentin (Cell Signaling Technology, Inc.), and b-actin (SigmaAldrich). The Enhanced Chemiluminescence Detection System (Pierce), followed by autoradiography, was used for protein visualization. Protein bands were quantified using densitometry software (Bio-Rad) and normalized using actin as a loading control. To calculate the relative intensity of each band, individual bands were divided by the corresponding loading control intensity.
Immunofluorescence
Cells were plated on a glass bottom culture dish (MatTek Corporation) at a density of 0.3 Â 10 6 cells per dish. Cells were grown to approximately 50% confluence in chamber slides and then treated with or without TGFbR1 blocker for 2 hours before treatment with either vehicle, progesterone, TGFb1, or a combination of progesterone and TGFb1 for a 24-hour period. After treatment, cells were washed twice with PBS and fixed with 4% paraformaldehyde for 15 minutes. Cells were then permeabilized with 100% methanol at À20 C, and care was taken to prevent desiccation of the samples. After complete removal of methanol, the samples were blocked using buffer prepared with normal goat serum for 60 minutes. SMAD2/3 antibody (Santa Cruz Biotechnology) diluted at 1:250 was applied overnight at 4 C. After complete removal of primary antibody, the diluted secondary antibody, Alexa Fluor 488 Goat Antimouse IgG (Invitrogen; Cat# A-11001), was applied. Samples were incubated for 2 hours at room temperature in the dark. Once excess secondary antibody was removed by rinsing with PBS, 4 0 ,6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI, 1 mg/mL; Sigma) was applied to cover for 30 seconds in the dark and then rinsed away with PBS. Coverslips were then mounted with Prolong Gold Antifade Reagent (Invitrogen; Cat# P36930). Slides were imaged on a Zeiss Pascal Confocal Microscope (Carl Zeiss Microscopy GmbH) immediately following preparation. Z stack slices obtained through confocal microscopy were then summed in ImageJ (NIH).
Statistical analysis
Data are presented as the mean of triplicate determinants with SEM. Experiments carried out in triplicate were repeated at least 3 times. Statistically significant differences were determined between control and treatment groups using two-way ANOVA followed by the Tukey post hoc test. A P value of less than 0.05 was considered statistically significant. Western blots were quantified using densitometry. A representative of 3 immunoblots is presented in the figures along with average relative density of the bands normalized to b-actin. Statistically significant differences were determined between control and treatment groups by quantification of 3 immunoblots, and p values are provided in the results section.
Results
Progesterone attenuates TGFb ligands in endometrial cancer cells
Endometrial tumors have been reported to express high levels of three TGFb isoforms and TGFb receptors in vivo (6). In addition, it has been suggested that TGFb1 plays a major role in the initiation of endometrial carcinoma invasion (21) . To determine whether progesterone regulates the expression of TGFbs and their receptors, HEC-1B, Ishikawa, and RL-95 human endometrial carcinoma cell lines were exposed to progesterone for 24, 72, and 120 hours. Exposure of endometrial cells to progesterone for 120 hours showed significantly decreased expression of TGFb1, -b2, and -b3 in all cell lines tested. All isoforms showed a marked decrease in expression following 72 hours of exposure except for TGFb2 and TGFb3 in HEC-1B and Ishikawa cells, respectively. In RL-95 cells, all three TGFb isoforms showed a significant decrease with progesterone in 72 hours of culture. No alteration of TGFb isoforms was seen in any cell line with progesterone in the first 24 hours of exposure (Fig. 1A) .
Progesterone inhibits latent TGFb concentration in the culture medium of cancer cells
To ascertain if progesterone regulates secretion of TGFb, the amount of TGFb secreted into the culture media was assayed by ELISA. As evident in Fig. 1B , cells exposed to TGFb1 secreted high levels of latent TGFb compared with vehicle-treated cells. TGFb secretion by endometrial cancer cells was markedly inhibited by addition of 20 mmol/L progesterone for 72 hours compared with vehicle-treated cells. TGFb1-induced secretion of latent TGFb was attenuated by progesterone. No such inhibiting effect was observed in the culture media of cells treated with progesterone receptor antagonist (Mifepristone) and progesterone or TGFb1 progesterone combination. Mifepristone-treated cells showed no effect on TGFb. These results clearly suggest that cancer cells secrete TGFb, and progesterone, at least in vitro, inhibits basal and TGFb1-induced secretion. Downregulation of TGFb was blocked by the antagonist Mifepristone providing evidence for the specificity of progesterone action in cancer cells.
TGFb receptors are downregulated by progesterone in endometrial cancer cells
TGFb acts through a membrane-associated receptor complex. We evaluated the protein expression of TGFbR1, TGFbR2, and TGFbR3 in endometrial cultures exposed to progesterone for 24, 72, and 120 hours. In HEC-1B cells, expression of TGFbR1, TGFbR2, and TGFbR3 was significantly (P < 0.05) downregulated following progesterone exposure for 72 and 120 hours compared with vehicletreated cells. Ishikawa cells showed a marked reduction of TGFbR1 expression at 120 hours of cell culture with progesterone, whereas TGFbR2 and TGFbR3 were inhibited at 72 and 24 hours, respectively. Progesterone inhibited TGFbR3 expression in RL-95 at 72 and 120 hours exposure and had no effect on TGFbR1 and TGFbR2 at any time point (Fig. 2) .
SMAD expression is inhibited by progesterone in endometrial cancer cells
In the canonical signaling pathway, SMAD phosphorylation is an indicator of functional TGFb receptors. To confirm that progesterone inhibits TGFb signaling transduction, protein levels of downstream SMADs were investigated. We examined levels of total and phosphorylated SMAD2/3 (p-SMAD2/3) in endometrial cancer cells exposed to progesterone for 24, 72, and 120 hours. Incubation with an antibody recognizing p-SMAD2 and 3 at Serine 423/425 showed that SMAD2/3 is phosphorylated in nontreated cancer cells. A significant reduction in SMAD2/3 and pSMAD2/3 was apparent 72 and 120 hours after exposure to progesterone in all cell lines except RL-95, where pSMAD2/3 showed significant inhibition at 24 hours of treatment. Total and pSMAD2/3 levels were not affected by progesterone in HEC-1B and Ishikawa cells during the first 24 hours of treatment (Fig. 3) . These results imply that progesterone is a potent TGFb antagonist in endometrial cancer cells. HEC-1B and Ishikawa cells exposed to progesterone for 72 and 120 hours showed pronounced decrease in SMAD4 expression. RL-95 cells exhibited a marked decrease in SMAD4 expression after 24 hours of progesterone treatment (Fig. 3) .
Furthermore, we investigated the effect of progesterone on the TGFb1-induced subcellular localization of SMAD2/3 in HEC-1B and Ishikawa endometrial cancer cells. In vehicle-treated cells, SMAD2/3 was expressed in the cytoplasm and in the nucleus. Progesterone and TGFb1 treatment decreased cytoplasmic SMAD2/3 ( Fig. 4A and C) . To establish that high SMADs localization in cancer cells is activated via an autocrine pathway, endometrial cancer cells pretreated with the TGFb receptor I blocker and then exposed to TGFb1 or a combination of TGFb1 and progesterone showed significantly attenuated nuclear localization of SMAD2/3 ( Fig. 4B and D) compared with non-TGFb receptor I blocker pretreated cells (Fig. 4A and C) . These findings strongly suggest that nuclear localization of SMAD2/3, which is an indication of the activated TGFb/SMAD signaling pathway, is attributed to TGFb produced and secreted by endometrial cancer cells.
Progesterone attenuates TGFb-mediated cell viability and invasion
TGFb1 has a principal role at the initiation of endometrial carcinoma invasion through the promotion of the EMT that leads to the acquisition of an invasive phenotype. In addition, although TGFb1 is a potent inhibitor of proliferation of most types of normal epithelia, it has a paradoxical proliferative effect in carcinomas (30) . To explore the effect of progesterone and TGFb1 on cell proliferation and invasion, we examined the effect of progesterone, TGFb1, or the combination in the presence or absence of TGFbR1 blocker (72 hours) on cell viability and cellular invasiveness. As shown in Fig. 5A , TGFb1 treatment of endometrial cancer cells induced a marked increase in cell viability compared with cells treated with vehicle. As expected, progesterone alone inhibited cell viability. Interestingly, progesterone markedly abrogated TGFb1-induced cell viability in both cell lines shown. TGFb1 failed to enhance cell viability in the presence of TGFbR1 blocker. Moreover, progesteroneinduced inhibition of cell viability was attenuated by TGFbR1 blocker.
The effects of progesterone and TGFb1 on the invasiveness of HEC-1B and Ishikawa cell lines were determined by using a boyden chamber invasion assay. Treatment of endometrial cancer cells with TGFb1 produced a significant increase in invasiveness as compared with vehicle-treated control. In addition, HEC-1B and Ishikawa cells treated with progesterone alone, or TGFb1 and progesterone in combination, underwent significant decreases in invasiveness when compared with vehicle-treated cells and TGFb1-treated cells, respectively (Fig. 5B) . TGFbR1 blocker markedly reduced the antitumorigenic effect of progesterone on cell invasiveness. These results demonstrate that progesterone inhibits both basal and exogenous TGFb1-induced promigratory and invasive activity of endometrial cancer cells by suppressing TGFb signaling.
Progesterone reduces expression of mesenchymal markers and inhibits EMT process
The EMT process, which is a crucial step in tumor progression, can be induced by several cytokines and chemokines, including TGFb (4). To examine if a progesteroneinduced decrease in cell invasiveness is associated with the EMT process, we evaluated the expression of EMT marker proteins (vimentin and E-cadherin) in extracts of HEC-1B and Ishikawa cells treated with vehicle, progesterone, TGFb1, or combination of progesterone and TGFb1 for 72 hours. Vimentin was upregulated and E-cadherin was downregulated in vehicle-treated cells. The TGFb1-exposed cells showed decreased expression of E-cadherin and enhanced expression of vimentin. Progesterone treatment caused a significant decrease in vimentin and an increase in E-cadherin expression in cancer cells. A similar expression pattern was observed in TGFb1-and progesterone-exposed cells. These results suggest that progesterone inhibits the EMT process in endometrial cancer cells (Fig. 6 ). 
Discussion
A strong body of clinical evidence has shown that progestins are potent inhibitors of endometrial carcinogenesis. Routine use of progestin-containing oral contraceptives markedly lowers endometrial cancer risk by as much as 30% or more (31, 32) . In addition, high-dose progestin therapy has been shown to reverse preexisting PTEN-inactivated endometrial latent precursors, as well as endometrial hyperplasia and even-low grade endometrial cancer in some women (33) (34) (35) .
TGFb can play multiple roles in carcinogenesis, acting as a tumor suppressor at early stages and a tumor promoter at late stages (2, 4) . Impairment of the TGFb-SMAD pathway can result in loss of restraint of growth, initiation of cell proliferation, and carcinogenesis (36, 37) . There is a paucity of information available about the effect of progesterone on TGFb/SMAD signaling in endometrial carcinoma cells. To fill this data gap, we explored the antitumor effect of progesterone on TGFb signaling at three levels: ligands, receptors, and SMADs. High levels of TGFbs are present in endometrial carcinoma cells in vitro and in vivo (38) (39) . TGFb isoforms have been shown to act on endometrial cell growth by autocrine or paracrine mechanisms and are implicated in several processes of tumorigenesis and metastasis (8) . In the current study, progesterone inhibited expression of TGFb ligands in all of the tested endometrial cancer cell lines. Our study provides clear evidence that the TGFb produced and secreted by endometrial cancer cells is inhibited by progesterone, and the progesterone receptor antagonist Mifepristone abolished progesteroneinduced inhibition of TGFb secretion from endometrial cancer cells.
TGFb mediates its effects from the surface of cells to the nucleus through TGFb receptors. Thus, TGFbRs are the gateways of intracellular signaling (4). Therefore, drugs blocking TGFb receptors' intracellular activity are urgently needed to inhibit TGFb-induced tumor progression. In the present report, we show that one of the possible mechanisms by which progesterone inhibits cancer cells viability and invasiveness is through targeting TGFbRs as evident by a marked decrease in TGFbR1, TGFbR2, and TGFbR3 expression.
The TGFbR3 plays a vital role in presenting TGFb to the signaling receptors, enhancing receptor-ligand interactions and promoting the cooperation between TGFb type I and II receptors. Decreasing the expression of TGFbR3 in endometrial cancer cells lines by progesterone may lead to decreased endometrial responsiveness to TGFb, which is a natural modulator of endometrial cell proliferation and ultimately inhibition of endometrial cancer cells invasion and metastasis.
SMAD proteins are major signaling molecules acting downstream of TGFb receptors. In normal cells, RSMADs are predominantly concentrated in the cytoplasm. Upon binding of TGFb to TGFbR2 and phosphorylation of TGFbR1, the activated receptor complex phosphorylates SMAD2/3, which forms a complex with SMAD4. This complex then translocates into the nucleus (4). We analyzed the localization of SMAD2/3 and its nuclear translocation in TGFb1 and progesterone-treated endometrial cancer cells. SMAD2/3 was found in the cytoplasm of endometrial cancer cells. However, it was found at even higher levels in the nucleus, despite the absence of exogenous TGFb1. This indicates constitutive activation of the SMAD pathway. This can be explained by the fact that endometrial cancer cells secrete TGFbs, which activate the signaling pathway by an autocrine mechanism. As a result, SMADs eventually translocate into the nucleus where they interact with other transcription factors to induce or repress transcription of a number of target genes. Our findings show that TGFb1 treatment of the cells caused translocation of SMAD2/3 from the cytoplasm to the nucleus. Progesterone reduced SMAD2/3 in the cytoplasm. This suggests disruption of SMAD signaling may be in part the mechanism by which progesterone affects tumor cell growth. To establish that SMAD activation in endometrial cancer cells is via an autocrine pathway, cells exposed to TGFbR1 blocker showed lack of SMAD2/3 nuclear localization compared with cells where TGFbR1 was not blocked. These findings substantiate that endometrial cancer cells secrete TGFb, which activate the signaling pathway by an autocrine mechanism. The discrepancy between confocal results and timedependent effect of progesterone on SMAD2/3 expression in endometrial cancer cells by Western blotting can be explained by the fact that confocal microscopy is more sensitive than Western blotting. Thus, small decrease of SMAD2/3 in the cytoplasm was not detected by Western blotting. However, when cells were exposed to progesterone for a longer period of time, a marked decrease in SMAD2/3 observed in total cellular extracts can be attributed to an overall decrease in TGFb/SMAD signaling pathway components and could be implicated in the observed decrease in cell viability and invasion. Because the findings reported herein suggest a role of progesterone in regulation of the TGFb/SMAD signaling pathway, it is conceivable that the response of cells to progesterone depends on progesterone receptors. In our recently published study (40) , we have shown reduced expression of both isoforms (PR-A and PR-B) in cancer (Ishikawa, HEC-1B, and RL95-2) cell lines compared with an immortalized endometrial epithelial (EM-E6/E7-TERT) cell line, and no marked changes were noticed in the expression of progesterone receptor isoforms in immortalized cells and in endometrial cancer cells following progesterone treatment. Treatment of endometrial cancer cells with progesterone caused a dose-dependent decrease in cell viability, and progesterone receptor antagonist abrogated that effect (29) , suggesting the presence of functional progesterone receptors on endometrial cancer cells. Levels of progesterone receptor expression vary in cancer cell lines, which would explain the differences in the time required for progesterone to downregulate TGFb, TGFbRs, and SMADs among cancer cell lines.
Our results showed reduced levels of TGFb secreted into culture media of cells exposed to progesterone compared with vehicle-treated cells. Abrogation of progesterone-induced decrease of TGFb into culture media of cells exposed to progesterone receptor antagonist is a testament of the fact that reduction of TGFb by progesterone is mediated through progesterone receptors. Furthermore, treatment of endometrial cancer cells with progesterone inhibited TGFb-induced SMAD2 translocation in the nucleus. This effect was not observed when cancer cells were cultured with the progesterone receptor antagonist C o n t r o l T G F β 1 Mifepristone (results not shown). These findings strongly suggest that alterations in TGFb signaling pathway components are specifically mediated by progesterone.
Results presented herein demonstrated a decrease in basal and TGFb1-induced viability, and invasive potential of endometrial cells exposed to progesterone. TGFbR1 blockade has shown effects on cellular responses, such as cellcycle arrest and EMT of epithelial cells in vitro (41, 42) . The fact that TGFbR1 blocker could completely block TGFb1-induced viability and invasion and markedly attenuated progesterone-induced suppression of both phenotypes suggests that progesterone is exerting its effects via the TGFb/ SMAD signaling pathway. A significant decrease in cell viability and invasion seen with progesterone in TGFbR1 blocker-treated cells indicates that progesterone uses other pathways as well to inhibit malignant phenotypes. These results are in agreement with studies demonstrating that blocking TGFb receptors inhibits TGFb1-induced proliferation and reduces the invasive and metastatic potential of human glioma colon, breast, and pancreatic cancer cells (42) (43) (44) .
In the present study, the inhibitory effect of progesterone treatment alone on cell viability and invasion is more potent than blocking TGFbR. In the previous study, we investigated the effects of progesterone on endometrial cancer cells and identified its targets of action using mass spectrometry-based proteomics. A total of 278 proteins, including histone H1.4 (HIST1H1E), histidine triad nucleotide-binding protein 2 (HINT2), IFNinduced, double-stranded RNA-activated protein kinase (EIF2AK2), and Bcl-2-associated X protein (BAX), showed differential expression with progesterone (40) . The dominant inhibitory effect of progesterone on cell viability and invasion can be attributed to upregulation of several tumor suppressor proteins suppressing cancer cell viability and invasive potential independent of the TGFb signaling pathway.
Although many signaling pathways have been implicated in the regulation of cell migration and invasion, TGFb is known to be a major modulator of tumor cell migration (4, 45) and invasion, partly due to its promotion of EMT (2) . TGFb has emerged as a promising target for treatment of cancer metastasis (4) . The expression of TGFb1 is increased in various tumors, including endometrial cancer, and correlates with poor patient prognosis (11, 45) . TGFb1 triggers EMT by direct phosphorylation of SMAD2/3, nuclear translocation of active SMAD complexes, and subsequent interactions with the general transcription machinery. As a result, cells become invasive, lose epithelial characteristics, and acquire a mesenchymal phenotype characterized by migration and invasion (46, 47) . This process is associated with the reduction of E-cadherin and the increase of Ncadherin and vimentin, allowing cells to become more motile and invasive (14, 48) . Reduced E-cadherin expression in endometrial tumors has been reported (49) . Herein, we showed that progesterone decreased the invasiveness of endometrial cancer cells via upregulation of E-cadherin and downregulation of vimentin. These findings are supported by a study that implicates progesterone in inhibiting EMT in endometrial cancer (49) .
Our work suggests that endometrial cancer cells have an intact TGFb pathway as they respond to TGFb and proliferation is reduced by adding TGFbR blocker. Endometrial cancer cells receive a myriad of signals from the tumor microenvironment, and the interpretation of these signals ultimately results in the enhancement of cellular responses (e.g., growth, migration, invasion). With respect to TGFb/ SMAD signaling, target gene transcription is dictated by nuclear accumulation of the activated SMAD complex and subsequent interaction with nuclear transcription factors and cofactors and activation of tumor promoting genes. Hence, suppression of the activated TGFb pathway by progesterone may be a new avenue for potential therapy in human endometrial tumors.
In summary, these findings suggest that progesterone markedly suppresses the TGFb pathway in endometrial cancers. Progesterone suppresses expression of the TGFb ligands, thus inhibiting autocrine TGFb-mediated growth of tumor cells. Progesterone also suppresses TGFb downstream signaling events via suppression of TGFb receptors and SMADs. These inhibit the metastatic characteristics of endometrial cancer cells by increasing E-cadherin and decreasing vimentin expression. These data suggest that modification of TGFb signaling may be a major mechanism underlying the anticancer effects of progesterone in the endometrium.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. .
Disclaimer
The opinions and assertions expressed herein are those of the authors and should not be construed as reflecting those of the Uniformed Services University of the Health Sciences, Department of the Air Force, or the U.S. Department of Defense. 
